CSIMarket
 


Renovorx Inc   (RNXT)
Other Ticker:  
 

Renovorx Inc 's Working Capital Ratio

RNXT's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


Renovorx Inc 's Current Assets grew by 38.43 % in the II Quarter 2023 sequentially, faster than Current Liabilities, this led to improvement in Renovorx Inc 's Working Capital Ratio to 3.72, Working Capital Ratio remained below Renovorx Inc average.

Within Major Pharmaceutical Preparations industry 280 other companies have achieved higher Working Capital Ratio than Renovorx Inc in second quarter 2023. While Working Capital Ratio total ranking has improved so far during the II Quarter 2023 to 1155, from total ranking in the first quarter 2023 at 1317.

Explain Working Capital Ratio
How much in Current Assets RNXT´s has?
What is the value of RNXT´s Current Liabilities?


RNXT Working Capital Ratio (Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
Y / Y Current Liabilities Change 51.29 % -7.18 % 17.48 % 76.32 % -
Y / Y Current Assets Change -43.84 % -67.29 % -55.38 % -49.08 % -
Working Capital Ratio MRQ 3.72 3.5 6.59 8.39 10.01
RNXT's Total Ranking # 1155 # 1317 # 836 # 685 # 469
Seq. Current Liabilities Change 30.19 % 18.42 % 0 % -1.87 % -20.13 %
Seq. Current Assets Change 38.43 % -37.22 % -21.46 % -17.73 % -19.36 %



Working Capital Ratio second quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 281
Healthcare Sector # 514
Overall Market # 1155


Working Capital Ratio Statistics
High Average Low
29.06 11.07 3.5
(Sep 30 2021)   (Mar 31 2023)




Financial Statements
Renovorx Inc 's Current Liabilities $ 2 Millions Visit RNXT's Balance sheet
Renovorx Inc 's Current Assets $ 6 Millions Visit RNXT's Balance sheet
Source of RNXT's Sales Visit RNXT's Sales by Geography


Cumulative Renovorx Inc 's Working Capital Ratio

RNXT's Working Capital Ratio for the trailling 12 Months

RNXT Working Capital Ratio

(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
Y / Y Current Liabilities TTM Growth 51.29 % -7.18 % 17.48 % 76.32 % -
Y / Y Current Assets TTM Growth -43.84 % -67.29 % -55.38 % -49.08 % -
Working Capital Ratio TTM 5.26 6.98 8.81 11.1 14.57
Total Ranking TTM # 935 # 1124 # 653 # 504 # 3595
Seq. Current Liabilities TTM Growth 30.19 % 18.42 % 0 % -1.87 % -20.13 %
Seq. Current Assets TTM Growth 38.43 % -37.22 % -21.46 % -17.73 % -19.36 %


On the trailing twelve months basis Due to growth in Current Liabilities in the II Quarter 2023 to $1.70 millions, cumulative Working Capital Ratio decreased to 5.26 below the Renovorx Inc average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 280 other companies have achieved higher Working Capital Ratio than Renovorx Inc . While Working Capital Ratio overall ranking has improved so far to 935, from total ranking during the twelve months ending first quarter 2023 at 1124.

Explain Working Capital Ratio
How much in Current Assets RNXT´s has?
What is the value of RNXT´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 281
Healthcare Sector # 514
Within the Market # 935


trailing twelve months Working Capital Ratio Statistics
High Average Low
29.06 11.07 3.5
(Sep 30 2021)   (Mar 31 2023)




Companies with similar Working Capital Ratio in the quarter ending Jun 30 2023, within Major Pharmaceutical Preparations Industry Working Capital RatioJun 30 2023 MRQ Current AssetsJun 30 2023 MRQ Current Liabilities
Kronos Bio Inc   10.16 $ 224.122  Millions$ 22.055  Millions
Lexicon Pharmaceuticals Inc   10.10 $ 263.720  Millions$ 26.109  Millions
Cadrenal Therapeutics Inc   10.05 $ 3.519  Millions$ 0.350  Millions
Aldeyra Therapeutics Inc   10.05 $ 155.479  Millions$ 15.475  Millions
Indaptus Therapeutics Inc   9.92 $ 19.873  Millions$ 2.003  Millions
Verrica Pharmaceuticals Inc   9.91 $ 56.777  Millions$ 5.731  Millions
Werewolf Therapeutics Inc   9.82 $ 147.399  Millions$ 15.006  Millions
Cassava Sciences Inc  9.75 $ 174.533  Millions$ 17.895  Millions
United Therapeutics Corporation  9.74 $ 3,213.400  Millions$ 329.800  Millions
Virpax Pharmaceuticals Inc   9.69 $ 15.951  Millions$ 1.647  Millions
Prothena Corporation Public Limited Company  9.46 $ 677.103  Millions$ 71.565  Millions
Ligand Pharmaceuticals Incorporated  9.42 $ 276.711  Millions$ 29.388  Millions
Clene Inc   9.31 $ 53.371  Millions$ 5.735  Millions
Ac Immune Sa  9.22 $ 125.153  Millions$ 13.576  Millions
Immuron Limited  9.20 $ 20.409  Millions$ 2.219  Millions
Glycomimetics Inc   9.19 $ 60.421  Millions$ 6.572  Millions
Verastem inc   9.14 $ 189.963  Millions$ 20.787  Millions
Sol gel Technologies Ltd   9.10 $ 41.167  Millions$ 4.522  Millions
Rocket Pharmaceuticals Inc   9.09 $ 312.074  Millions$ 34.346  Millions
Igm Biosciences Inc   9.07 $ 401.760  Millions$ 44.299  Millions
Oncolytics Biotech Inc   9.01 $ 29.241  Millions$ 3.246  Millions
Scynexis Inc   9.01 $ 145.530  Millions$ 16.158  Millions
Pepgen Inc   8.88 $ 150.378  Millions$ 16.936  Millions
An2 Therapeutics Inc   8.80 $ 98.206  Millions$ 11.161  Millions
Lumos Pharma Inc   8.79 $ 55.983  Millions$ 6.366  Millions
Crinetics Pharmaceuticals Inc   8.75 $ 285.478  Millions$ 32.610  Millions
Nektar Therapeutics  8.70 $ 441.058  Millions$ 50.694  Millions
Oragenics Inc   8.52 $ 8.099  Millions$ 0.951  Millions
Pulmatrix Inc   8.45 $ 27.381  Millions$ 3.239  Millions
Lixte Biotechnology Holdings Inc   8.44 $ 3.095  Millions$ 0.367  Millions

Date modified: 2023-08-18T12:07:13+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com